卡介苗疗法治疗急性非淋巴细胞白血病。
BCG therapy in acute non lymphoid leukaemias.
作者信息
Vuvan H, Fiere D, Doillon M, Martin C, Coiffier B, Felman P, Bryon P A, Favre-Gilly J, Revol L
出版信息
Scand J Haematol. 1978 Jul;21(1):40-6. doi: 10.1111/j.1600-0609.1978.tb02493.x.
The survival of patients with acute non-lymphoid leukaemias (ANLL) receiving chemotherapy (32 patients) or chemotherapy plus BCG (31 patients) has been compared in a randomized trial which started in Nov 1974. Fresh BCG (Institut Pasteur, Paris) was administered by Heaf gun in the interval of chemotherapy cycles. The overall survival was better in the chemo-immunotherapy group (median duration of survival of 25 months compared to 16 months in the chemotherapy group). However, the first remission duration did not differ (median duration of the 15 and 12 months, respectively). Plateau survival curves were not obtained in either group. A second complete remission was obtained in 7 out of 12 patients with bone marrow relapses in the chemo-immunotherapy group, and only in 2 out of 15 in the chemotherapy group (P less than 0.05). BCG seemed more efficient in patients older than 40 years; no difference was observed according to sex.
在一项始于1974年11月的随机试验中，对接受化疗的急性非淋巴细胞白血病（ANLL）患者（32例）和接受化疗加卡介苗（BCG）的患者（31例）的生存率进行了比较。在化疗周期的间歇期，用Heaf枪接种新鲜的卡介苗（巴黎巴斯德研究所生产）。化疗免疫治疗组的总生存率更高（中位生存期为25个月，而化疗组为16个月）。然而，首次缓解期并无差异（分别为15个月和12个月）。两组均未获得平台期生存曲线。化疗免疫治疗组12例骨髓复发患者中有7例获得第二次完全缓解，而化疗组15例中只有2例（P<0.05）。卡介苗对40岁以上患者似乎更有效；未观察到性别差异。
Zotero 插件